<div id="readability-page-1">05:42 PM EST, 12/03/2025 (MT Newswires) -- Apellis (APLS) said Wednesday the New England Journal of Medicine published positive Phase 3 results for Empaveli, its treatment for rare kidney diseases.The study showed a 68% reduction in proteinuria, the presence of an abnormal amount of protein in the urine, at Week 26, along with stabilization of kidney function and reduced C3 staining, the company said.Results were consistent across adults and adolescents, including patients whose disease returned after a transplant. Empaveli is already Food and Drug Administration-approved for patients 12 and older.Shares of the company were up over 1% in after-hours trading. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

APLS

Apellis（APLS）公佈了其腎病治療藥物 Empaveli 的積極第三階段臨牀試驗結果，相關研究發表在《新英格蘭醫學雜誌》上。研究顯示，在第 26 周時，蛋白尿減少了 68%，腎功能穩定，C3 染色減少。結果在成年人和青少年中一致，包括移植後患者。Empaveli 已獲得 FDA 批准，適用於 12 歲及以上的患者。盤後交易中，股價上漲超過 1%

Apellis 報告其腎病治療藥物 Empaveli 的三期試驗結果呈現積極效果